Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02227459 · ClinicalTrials.gov registry record · Phase 1
Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)
A Phase 1 study of Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4), sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT02227459 is a Phase 1 study of Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4) that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 25 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT02227459, a Phase 1 study of Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4), has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of multiple doses of ND-L02-s0201 in subjects with moderate to extensive hepatic fibrosis.
Conditions Studied
Interventions
- DRUG ND-L02-s0201 Injection
Study Locations (2)
Texas
- Texas Liver Institute - Austin
Other
- Tokuda Hospital - Sofia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02227459
The ClinicalTrials.gov registry entry for NCT02227459 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4) appearing as the primary indexed condition, and to 1 intervention - of which ND-L02-s0201 Injection is the first listed.
NCT02227459 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Other.
Frequently Asked Questions
What is clinical trial NCT02227459 about?
NCT02227459 is a clinical study titled "Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)". The purpose of this study is to evaluate the safety and tolerability of multiple doses of ND-L02-s0201 in subjects with moderate to extensive hepatic fibrosis.
What is the current status of trial NCT02227459?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2014-10. Estimated completion is 2016-05.
What conditions does trial NCT02227459 study?
This clinical trial studies the following conditions: Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4).
What interventions are being tested in trial NCT02227459?
The interventions under investigation include: ND-L02-s0201 Injection (DRUG).
Who is sponsoring clinical trial NCT02227459?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02227459 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.